Abstract
In curatively resected gastric cancer, the incidence of distant relapse is as high as 30%. Although the most important factor contributing to the local control of the tumor is the microscopic tumor-free margin of the surgical resection, the occurrence of distant metastases is in many cases due to preoperative or perioperative tumor cell dissemination. In addition to the established TNM staging system, disseminated tumor cells may serve as independent prognostic factors influencing patient outcome after curative surgery. Basically, in gastric cancer three compartments have been identified in which single tumor cells may be shed: lymph nodes, peritoneal cavity, and bone marrow. Assessment of resected regional lymph nodes with monoclonal antibodies directed against cytokeratin antigens leads to an upstaging in comparison with conventional histology. Nodal micrometastases detected by immunohistochemistry result in an upstaging of up to 36% of patients. However, their prognostic significance remains controversial. Local dissemination of tumor cells in the peritoneal cavity determines the outcome in advanced gastric cancer and diffuse-type carcinoma. Patients with negative peritoneal washings seem to have a more favorable prognosis. Moreover, with the use of these diagnostic tools, patient subpopulations may be identified which profit from intraperitoneal therapy regimens. Diffuse hematogenous tumor cell dissemination into the bone marrow has been shown to be a prognostic factor in several studies. In our own population of 180 gastric cancer patients, bone marrow cells were screened immunohistochemically with a monoclonal antibody directed against cytokeratin 18 (CK18). In 95 patients (53%), CK2-posititve cells were detected. In a multivariate analysis, the independence of the presence of three or more disseminated tumor cells per 106 mononuclear cells was proven to be a prognostic factor in patients with intestinal-type tumors, pTl/2 status, and pN0 status. In conclusion, the TNM status only partially reflects the actual extent of systemic disease in patients with resected gastric cancer. The assessment of minimal residual disease is valuable in estimating the prognosis in many patients. In the future, staging systems will have to not only include TNM data but also provide specific information on biological properties of residual cancer cells in order to establish more exact prognostic estimates and provide patients with an individually tailored multimodal treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Doglietto GB, Pacelli F, Caprino P, Sgadari A, Crucitti F (2000) Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg 24 4:459–463
Müller P, Schlimok G (2000) Bone marrow “micrometastases” of epithelial tumors: detection and clinical relevance. J Cancer Res Clin Oncol 126:607–618
Schmid A, Kremer B (2000) Chirurgische Prinzipien beim Magencarcinom. Chirurg 71 8:974–986
Siewert JR, Kestlmeier R, Busch R, et al (1996) Benefits of D2 lymph node dissection for patients with gastric cancer and pNO and pNl lymph node metastases. Br J Surg 83: 1144–1147
Harrison LE, Choe JK, Goldstein M, Meridian A, Kim SH, Clarke K (2000) Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients. J Surg Oncol 73:153–157
Maehara Y, Oshiro T, Endo K, et al (1996) Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 119:397–402
Cai J, Ikeguchi M, Maeta M, Kaibara N (2000) Micrometastasis in lymph nodes and miroinvasion of the muscularis propria in primary lesions of submucosal gastric cancer. Surgery 127:32–39
Ishida K, Katsuyama T, Sugiyama A, Kawasaki S (1997) Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. Cancer 79:1069–1076
Fukagawa T, Sasako M, Mann GB, et al (2001) Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. Cancer 92:753–760
Kell MR, Winter DC, O’Sullivan GC, Shanahan F, Redmond HP (2000) Biological behaviour and clinical implications of micrometastases. Br J Surg 87:1629–1639
Vogel P, Rüschoff J, Kummel S, et al (1999) Immunocytology improves prognostic impact of peritoneal tumour cell detection compared to conventional cytology in gastric cancer. Eur J Surg Oncol 25:515–519
Schott A, Vogel I, Krueger U, et al (1998) Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227:372–379
Nakanishi H, Kodera Y, Yamamura Y, et al (1999) Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol 43 [Suppl]: S32-S36
Yonemura Y, Fujimura T, Ninomiya I, et al (2001) Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 7:1647–1653
Vogel P, Rüschoff J, Kümmel S, et al (2000) Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. Dis Colon Rectum 43:92–100
Bonavina L, Soligo D, Quirici N, et al (2001) Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 129:15–22
Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW (1997) Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 226:736–744
Jauch KW, Heiss MM, Gruetzner U, et al (1996) Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14:1810–1817
Funke I, Fries S, Rolle M, et al (1996) Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 65:755–761
Juhl H, Kalthoff H, Krüger U, Henne-Bruns D, Kremer B (1995) Immunzytologischer Nachweis mikrometastatischer Zellen bei Patienten mit gastrointestinalen Tumoren. Zen-tralbl Chir 120:116–122
Spatz H, Kerner T, Vogel P, Fürst A, Dietmaier W, Jauch KW (2000) Tumorzelldissemination und Metastasierung beim gastrointestinalen Karzinom: Mechanismen, Nachweis und Bedeutung. Viszeralchirurgie 35:375–384
Kerner T, Hauzenberger T, Jauch KW (1998) Nachweis und Bedeutung der Tumorzelldissemination beim Magenkarzinom. Onkologe 4:294–300
Heiss MM, Allgayer H, Gruetzner KU, et al (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1:1035–1039
Allgayer H, Heiss MM, Riesenberg R, et al (1997) Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 57:1394–1399
Maehara Y, Hasuda S, Abe T, et al (1998) Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 4:2129–2134
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Seeliger, H., Spatz, H., Jauch, KW. (2003). Minimal Residual Disease in Gastric Cancer. In: Allgayer, H., Heiss, M.M., Schildberg, F.W. (eds) Molecular Staging of Cancer. Recent Results in Cancer Research, vol 162. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59349-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-59349-9_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63945-6
Online ISBN: 978-3-642-59349-9
eBook Packages: Springer Book Archive